title: Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron.
abstract: Iron(II) heme-mediated activation of the peroxide bond of artemisinins is thought to generate the radical oxygen species responsible for their antimalarial activity. We analyzed the role of ferrous iron in the cytotoxicity of artemisinins toward tumor cells. Iron(II)-glycine sulfate (Ferrosanol) and transferrin increased the cytotoxicity of free artesunate, artesunate microencapsulated in maltosyl-beta-cyclodextrin, and artemisinin toward CCRF-CEM leukemia and U373 astrocytoma cells 1.5- to 10.3-fold compared with that of artemisinins applied without iron. Growth inhibition by artesunate and ferrous iron correlated with induction of apoptosis. Cell cycle perturbations by artesunate and ferrous iron were not observed. Treatment of p53 wild-type TK6 and p53 mutated WTK1 lymphoblastic cells showed that mutational status of the tumor suppressor p53 did not influence sensitivity to artesunate. The effect of ferrous iron and transferrin was reversed by monoclonal antibody RVS10 against the transferrin receptor (TfR), which competes with transferrin for binding to TfR. CCRF-CEM and U373 cells expressed TfR in 95 and 48% of the cell population, respectively, whereas TfR expression in peripheral mononuclear blood cells of four healthy donors was confined to 0.4-1.3%. This indicates that artemisinins plus ferrous iron may affect tumor cells more than normal cells. The IC(50) values for a series of eight different artemisinin derivatives in 60 cell lines of the U.S. National Cancer Institute were correlated with the microarray mRNA expression of 12 genes involved in iron uptake and metabolism by Kendall's tau test to identify iron-responsive cellular factors enhancing the activity of artemisinins. This pointed to mitochondrial aconitase and ceruloplasmin (ferroxidase).
authors.affiliation: Center for Molecular Biology, University of Heidelberg, Heidelberg, Germany. thomas.efferth@zmbh.uni-heidelberg.de
authors.forename: Thomas
authors.initials: T
authors.lastname: Efferth
authors.forename: Achille
authors.initials: A
authors.lastname: Benakis
authors.forename: Marta R
authors.initials: MR
authors.lastname: Romero
authors.forename: Maja
authors.initials: M
authors.lastname: Tomicic
authors.forename: Rolf
authors.initials: R
authors.lastname: Rauh
authors.forename: Daniel
authors.initials: D
authors.lastname: Steinbach
authors.forename: Ralf
authors.initials: R
authors.lastname: Häfer
authors.forename: Thomas
authors.initials: T
authors.lastname: Stamminger
authors.forename: Franz
authors.initials: F
authors.lastname: Oesch
authors.forename: Bernd
authors.initials: B
authors.lastname: Kaina
authors.forename: Manfred
authors.initials: M
authors.lastname: Marschall
mesh_terms: D015703:Antigens, CD / Q000378:metabolism; D000944:Antigens, Differentiation, B-Lymphocyte / Q000378:metabolism; D037621:Artemisinins / Q000633:toxicity*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D005296:Ferrous Compounds / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D020128:Inhibitory Concentration 50; D007501:Iron / Q000494:pharmacology*; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D011990:Receptors, Transferrin; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism
chemical_list: D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; D037621:Artemisinins; C068126:CD71 antigen; D005296:Ferrous Compounds; D012333:RNA, Messenger; D011990:Receptors, Transferrin; D016159:Tumor Suppressor Protein p53; D007501:Iron